Document is current
Any future updates will be listed below
-
Authors
Jost, Marco https://orcid.org/0000-0002-1369-4908
Santos, Daniel A. https://orcid.org/0000-0002-3757-189X
Saunders, Reuben A.
Horlbeck, Max A. https://orcid.org/0000-0002-3875-871X
Hawkins, John S.
Scaria, Sonia M.
Norman, Thomas M.
Hussmann, Jeffrey A. https://orcid.org/0000-0002-7778-9893
Liem, Christina R.
Gross, Carol A. https://orcid.org/0000-0002-5595-9732
Weissman, Jonathan S. https://orcid.org/0000-0003-2445-670X
- License Information
-
More Information
Article History
Received: 21 June 2019
Accepted: 5 December 2019
First Online: 13 January 2020
Competing interests
: J.S.W., M.J., D.A.S., R.A.S., M.A.H. and T.M.N. have filed patent applications related to CRISPRi/a screening, Perturb-seq and mismatched sgRNAs. J.S.W. consults for and holds equity in KSQ Therapeutics, Maze Therapeutics and Tenaya Therapeutics. J.S.W. is a venture partner at 5AM Ventures and a member of the Amgen Scientific Advisory Board. M.J., M.A.H. and T.M.N. consult for Maze Therapeutics.
